Kepler:" Upgrade to Buy RHI’s shares have been down almost 20% in the last month. Q2 results were okay (especially margins) and the slightly downwards revised outlook for 2014 (flat sales versus 3% growth previously, but margin outlook maintained) hasn’t justified the recent share price weakness in our view. As the valuation has become significantly more attractive recently and potential risks (economic slowdown, no quick fix at the underperforming Norwegian plant) now seem well priced in, we upgrade our ratomg from Hold to Buy.

New TP of EUR24

Following the reduced guidance, we have decreased our sales projections by 4% for 2014 and 2015. Our new EPS forecasts go down by 6% to EUR2.15 for 2014 and to EUR2.52 for 2015.

Conference call highlights

1) In the Steel division, RHI continues to see good demand in Europe, the Middle East and India, whereas CIS, Asia (ex-India) and South America look weak. Margins in the Steel division could be supported by better capacity utilisation after the closure of the Duisburg plant. 2) The underperforming Industrial division could see a clear improvement in H2 (sales and margins) due to a strong project pipeline (cement, non-ferrous metals, glass). However, management believes the higher project activity in H2 will not be able to fully offset lower sales in H1. Hence, the adjustment of the guidance. 3) In the Industrial division, the persistent weakness of the glass division could lead to the closure of the Russian plant (book value: EUR5m) and a refocusing of the US plant on other industries. 4) The weak FCF situation in H1 could mostly reverse in H2, as the build-up in inventories (EUR38m in H1) mainly related to projects which will be executed in H2. 5) At the Norwegian plant, RHI has made good progress in the fusion operations. However, the upstream caster process is still underperforming. As a result, the plant is still not cost competitive and the worst case (plant closure) is still an option. "

RHI

RHI: Letzter Schlusskurs (Euro): 20.700, das ist der 147. beste von 147 Handelstagen (%-Perf.) , das ist der 147. beste von 147 Handelstagen (Preis) , Periodenhoch am 22.01.14 (Kurs: 26.050 Δ% -20.54), Periodentief am 05.08.14 (Kurs: 20.700 Δ% 0), 147 Handelstage, davon ↑ 72 → 2 ↓ 73 , Performance Periode: -8.22 %, Umsatz '14/'13: 71 %

Zur Animation

Was noch interessant sein dürfte:

RBI und Erste wieder gleichauf, ein Blick auf die Lows (BSNgine Selected)

Alerts bei Evotec, BMW, Time Warner, Fresenius Medical Care - kommentierte Umsatzausreisser unter den Trendwerten (BSNgine Selected)

Neue ATX-Hackordnung (BSNgine Selected)

Alerts bei Gazprom, Drillisch, Evotec und adidas - kommentierte Umsatzausreisser unter den Trendwerten (BSNgine Selected)

SMA, adidas, DMG, Balda, Phoenix: Die grossen Wochenverlierer kommentiert (BSNgine Selected)

2x Fresenius als einzige DAX-Wochengewinner, Kommentare (BSNgine Selected)

Alerts bei Xing, Time Warner, Nestlé, Continental und ElringKlinger - kommentierte Umsatzausreisser unter den Trendwerten (BSNgine Selected)

ATX: Führungswechsel year-to-date (BSNgine Selected)

FACC: RCB sieht die Aktie zweistellig (BSNgine Selected)

Andritz mit 10 Prozent Potenzial für Baader, Blick auf die Aktie (BSNgine Selected)

Alerts bei Time Warner, DMG Mori Seiki, Evotec und Xing - kommentierte Umsatzausreisser unter den Trendwerten (BSNgine Selected)

Marketcap DAX: Zwei Titel fast gleichauf. (BSNgine Selected)

Random Partner

VIG
Die Vienna Insurance Group (VIG) ist mit rund 50 Konzerngesellschaften und mehr als 25.000 Mitarbeitern in 30 Ländern aktiv. Bereits seit 1994 notiert die VIG an der Wiener Börse und zählt heute zu den Top-Unternehmen im Segment “prime market“ und weist eine attraktive Dividendenpolitik auf.

>> Besuchen Sie 60 weitere Partner auf boerse-social.com/partner